This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Uveitis. Measurement will happen over the course of From baseline until 12 months post-randomization.
This trial requires 118 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
The current results are based on our best experience. The efficacy and tolerability, as determined by the number and type of patient reports, is generally very good. Immunosuppressive medicines, such as MMF, a subgroup of which is also used for treatment of GVHD, may decrease the prevalence of uveitis compared to other drugs. Some newer immunosuppressants, such as MMFX, may cause an increased prevalence of lymphocytic choriomeningitis (LCM). MMFX treatment should thus usually be withheld during the time frame for LCM.
Uveitis refers to a group of pathological conditions of the eyes. The presentation of uveitis varies and should be evaluated with special attention because, in a varying percentage, uveitis is the most common manifestation of an autoimmune disease. All sorts of ophthalmological problems can be attributed to uveitis, from simple and trivial to serious to life-threatening. The management of uveitis is, therefore, a complicated process, requiring the consultation of many professionals with the aim of ensuring a successful outcome. Most of the ophthalmologists of Switzerland treat patients with uveitis under referral of internists or rheumatologists.
The annual number of new diagnoses of uveitis appears to be on the rise, and the number of patients with uveitis may also be increasing. To the best of our knowledge, this is the first such report to describe the actual numbers of patients with uveitis annually in the United States.
In a large number of cases uveitis is caused by a systemic disease. Uveitis in patients with normal immune function appears to be caused in a number of cases by an immune disorder affecting one of the components of the retino-tracheal-bronchial-cerebro-spinal-fludrocortisone axis.
To treat uveitis one will need to find the reason for it. It can be tricky as there is no single cause for it, they are all intertwined and it’s possible that multiple factors are involved. The signs of uveitis can help pinpoint what is happening in the eyes. When a doctor and person are talking about what needs to be done, you should keep these in mind. They change and can take on many forms when it comes to uveitis. The most used signs can be redness, itchiness, blurred vision, and a white or yellowish (sometimes brown) fluid in the eye.
We believe that the future application of biologic therapy and synthetic compounds may yield an improvement in the management of refractory uveitis of both active and inactive nature.
Treatment for uveitis is generally based on the clinical picture and varies from one physician to another. In cases where uveitis is misdiagnosed, the disease can be fatal.
From our study, we concluded that the primary cause of uveitis is not the HLA-B27, but possibly a certain type of eye drops. However, we could not ascertain the cause of uveitis in all cases. It is only a clue. In addition, the cause may be different in cases of posterior uveitis and anterior uveitis. We will be conducting a clinical study focusing on new medicines which can treat uveitis.
Patients are at low risk for serious harm when receiving therapies in a clinical trial when these interventions seem to benefit patients. A more realistic perspective is that if our therapies do not work, it's because they don't work yet. It is possible that we could learn much more about treating uveitis if we study patients during their actual, everyday conditions that are very different from the laboratory settings used in most clinical trials. If we use treatments with which patients have long-term problems such as glaucoma or diabetic sight loss, we are unlikely to expect the results to be different from what they would be in those settings.
Uveitis treatment aims to stop inflammation and alleviate its pain and sight-threatening effects, as the eye may swell and become painful to close. The symptoms of uveitis depend on where the swelling occurs and what causes it. Eye-drops may contain steroids to reduce inflammation. Other drugs are usually prescribed to slow down or stop the production of proteins and fluids in the eye that produce inflammation. Doctors use a variety of approaches to treat and control inflammation or inflammation-inducing conditions. Examples of disease or conditions a person may have to deal with, and their treatment include multiple sclerosis, rheumatoid arthritis, multiple sclerosis-related spondylarthritis, thyroid disorders, cancer, psoriasis, eczema, and sepsis.
We found no evidence for a genetic etiology in non-specific, bilateral or familial nephritis in the first-degree relatives. Neither isolated nor familial uveitis was found. Based upon these findings, we hypothesize that non-specific uveitis is probably more heterogeneously triggered and is not transmitted through genes.